Posts are written by library staff and reflect their personal opinions not necessarily those of MSK.
The Scopus database now provides users the ability to easily identify OA content thanks to a collaboration with Impactstory. Users may now access over 8 million OA papers by applying the OA filter after running a search.
Link to Scopus from the MSK Library’s Databases A-Z list and if you have any questions about this resource or want to learn more about OA journals, please don’t hesitate to ASK US.
The Library has recently added Optimization of Behavioral, Biobehavioral, and Biomedical Interventions: The Multiphase Optimization Strategy (MOST) to our eBook collection.
Behavioral, biobehavioral, and biomedical interventions are programs with the objective of improving and maintaining human health and well-being.This volume is the first book to present a comprehensive introduction to the multi-phase optimization strategy (MOST), pioneered at The Methodology Center at the Pennsylvania State University, as an alternative to the classical approach of relying solely on the randomized controlled trial (RCT). Through numerous examples, the book demonstrates that MOST can be used to develop interventions that are more effective, efficient, economical, and scalable. This resource is essential for behavioral, biobehavioral, and biomedical scientists; statisticians, biostatisticians, and analysts working in epidemiology and public health.
Optimization of Behavioral, Biobehavioral, and Biomedical Interventions: The Multiphase Optimization Strategy (MOST) may be found in OneSearch.
A recent New England Journal of Medicine study indicates that post-surgical combination chemotherapy is more effective in patients with metastatic pancreatic cancer than the standard chemotherapy regimen. Researchers in Canada and France administered the combination chemotherapy, a modified FOLFIRINOX regimen, to 238 randomly selected eligible study participants and compared their outcomes to 243 participants receiving the standard post-surgical treatment, gemcitabine. On average, patients in the FOLFIRINOX group had 21.6 months of disease-free survival compared to 12.8 months in the gemcitabine group. In an Oncology Times article, MSK’s Dr. Alice Wei calls the study “practice changing.” The article notes that the chemotherapy regimen is not suitable for all pancreatic cancer patients, and that the combination chemotherapy can have more side effects.